CNBX Pharmaceuticals Inc.
CNBX
$0.00
$0.000.00%
OTC PK
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 302.97% | 12.83% | 73.91% | 2.53% | -63.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 302.97% | 12.83% | 73.91% | 147.05% | -73.47% |
| Operating Income | -302.97% | -12.83% | -73.91% | -147.05% | 73.47% |
| Income Before Tax | -158.29% | 36.82% | -230.52% | -147.69% | 54.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -158.29% | 36.82% | -230.52% | -147.69% | 54.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -158.29% | 36.82% | -230.52% | -147.69% | 54.29% |
| EBIT | -302.97% | -12.83% | -73.91% | -147.05% | 73.47% |
| EBITDA | -- | -- | -- | -112.76% | 85.36% |
| EPS Basic | 92.86% | 100.00% | 81.82% | 68.42% | 66.67% |
| Normalized Basic EPS | 88.89% | 100.00% | 85.71% | 66.67% | 65.38% |
| EPS Diluted | 92.86% | 100.00% | 81.82% | 68.42% | 66.67% |
| Normalized Diluted EPS | 88.89% | 100.00% | 85.71% | 66.67% | 65.38% |
| Average Basic Shares Outstanding | 2,995.48% | 2,800.65% | 2,255.59% | 723.76% | 36.92% |
| Average Diluted Shares Outstanding | 2,995.48% | 2,800.65% | 2,255.59% | 723.76% | 36.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |